candesartan has been researched along with Diabetic Angiopathies in 16 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analysed outcomes in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme which randomized 7599 patients with symptomatic HF and a broad range of EF." | 9.13 | Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. ( Granger, CB; MacDonald, MR; McMurray, JJ; Michelson, EL; Ostergren, J; Petrie, MC; Pfeffer, MA; Solomon, SD; Swedberg, K; Varyani, F; Young, JB; Yusuf, S, 2008) |
| "In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced." | 5.38 | Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. ( Briones, AM; Burger, D; Burns, KD; Callera, GE; Corrêa, JW; Gagnon, AM; Gomez-Sanchez, CE; Gomez-Sanchez, EP; He, Y; Nguyen Dinh Cat, A; Ooi, TC; Ruzicka, M; Sorisky, A; Touyz, RM; Yogi, A, 2012) |
| "We analysed outcomes in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme which randomized 7599 patients with symptomatic HF and a broad range of EF." | 5.13 | Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. ( Granger, CB; MacDonald, MR; McMurray, JJ; Michelson, EL; Ostergren, J; Petrie, MC; Pfeffer, MA; Solomon, SD; Swedberg, K; Varyani, F; Young, JB; Yusuf, S, 2008) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| "Aldosterone is an important pathogenetic factor, independent of the renin-angiotensin system in cardiovascular and renal disease." | 2.73 | Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007) |
| "Twenty-four asymptomatic patients with type 2 diabetes were randomly assigned to temocapril (2 mg/d) or candesartan (8 mg/d)." | 2.72 | Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist. ( Daimon, M; Hasegawa, R; Himi, T; Kawata, T; Komuro, I; Sekine, T; Teramoto, K; Toyoda, T; Uchida, D; Yamamoto, K; Yoshida, K, 2006) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| "In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced." | 1.38 | Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. ( Briones, AM; Burger, D; Burns, KD; Callera, GE; Corrêa, JW; Gagnon, AM; Gomez-Sanchez, CE; Gomez-Sanchez, EP; He, Y; Nguyen Dinh Cat, A; Ooi, TC; Ruzicka, M; Sorisky, A; Touyz, RM; Yogi, A, 2012) |
| "Focal cerebral ischemia, induced by middle cerebral artery occlusion/reperfusion (MCAO), was conducted at 4 wk after STZ injection." | 1.32 | Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. ( Granger, DN; Ishikawa, M; Kusaka, G; Kusaka, I; Nanda, A; Tang, J; Zhang, JH; Zhou, C, 2004) |
| "When hypertension was reduced using captopril or candesartan, retinal KDR expression returned to baseline levels." | 1.31 | Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. ( Aiello, LP; Clermont, A; Feener, EP; Hata, Y; Pokras, F; Rook, SL; Suzuma, I; Suzuma, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (81.25) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Fukuda, M | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Briones, AM | 1 |
| Nguyen Dinh Cat, A | 1 |
| Callera, GE | 1 |
| Yogi, A | 1 |
| Burger, D | 1 |
| He, Y | 1 |
| Corrêa, JW | 1 |
| Gagnon, AM | 1 |
| Gomez-Sanchez, CE | 1 |
| Gomez-Sanchez, EP | 1 |
| Sorisky, A | 1 |
| Ooi, TC | 1 |
| Ruzicka, M | 1 |
| Burns, KD | 1 |
| Touyz, RM | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, H | 1 |
| Ishikawa, M | 2 |
| Hosoya, T | 1 |
| Hayashi, T | 1 |
| Sohmiya, K | 1 |
| Ukimura, A | 1 |
| Endoh, S | 1 |
| Mori, T | 1 |
| Shimomura, H | 1 |
| Okabe, M | 1 |
| Terasaki, F | 1 |
| Kitaura, Y | 1 |
| Kusaka, I | 1 |
| Kusaka, G | 1 |
| Zhou, C | 1 |
| Nanda, A | 1 |
| Granger, DN | 1 |
| Zhang, JH | 1 |
| Tang, J | 1 |
| Miura, Y | 1 |
| Yamamoto, N | 1 |
| Tsunekawa, S | 1 |
| Taguchi, S | 1 |
| Eguchi, Y | 1 |
| Ozaki, N | 1 |
| Oiso, Y | 1 |
| Kawata, T | 1 |
| Daimon, M | 1 |
| Hasegawa, R | 1 |
| Teramoto, K | 1 |
| Toyoda, T | 1 |
| Sekine, T | 1 |
| Yamamoto, K | 1 |
| Uchida, D | 1 |
| Himi, T | 1 |
| Yoshida, K | 1 |
| Komuro, I | 1 |
| Iwashima, Y | 1 |
| Okada, M | 1 |
| Haneda, M | 1 |
| Yoshida, T | 1 |
| García Donaire, JA | 1 |
| Ruilope, LM | 1 |
| Banes-Berceli, AK | 1 |
| Ketsawatsomkron, P | 1 |
| Ogbi, S | 1 |
| Patel, B | 1 |
| Pollock, DM | 1 |
| Marrero, MB | 1 |
| Kinugawa, S | 1 |
| Yoneda, T | 1 |
| Takeda, Y | 1 |
| Usukura, M | 1 |
| Oda, N | 1 |
| Takata, H | 1 |
| Yamamoto, Y | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 1 |
| MacDonald, MR | 1 |
| Petrie, MC | 1 |
| Varyani, F | 1 |
| Ostergren, J | 1 |
| Michelson, EL | 1 |
| Young, JB | 1 |
| Solomon, SD | 1 |
| Granger, CB | 1 |
| Swedberg, K | 1 |
| Yusuf, S | 1 |
| Pfeffer, MA | 1 |
| McMurray, JJ | 1 |
| Suzuma, I | 1 |
| Hata, Y | 1 |
| Clermont, A | 1 |
| Pokras, F | 1 |
| Rook, SL | 1 |
| Suzuma, K | 1 |
| Feener, EP | 1 |
| Aiello, LP | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
3 reviews available for candesartan and Diabetic Angiopathies
| Article | Year |
|---|---|
Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinica | 2007 |
[Diabetic heart disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
6 trials available for candesartan and Diabetic Angiopathies
| Article | Year |
|---|---|
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2005 |
Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2006 |
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2007 |
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetic Angiopat | 2008 |
7 other studies available for candesartan and Diabetic Angiopathies
| Article | Year |
|---|---|
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2010 |
Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction.
Topics: Adipocytes; Aldosterone; Animals; Benzimidazoles; Biphenyl Compounds; Calcineurin; Cells, Cultured; | 2012 |
Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 2003 |
Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2004 |
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrasentan; Benzi | 2007 |
Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Captopril; Cat | 2001 |